Moleculin Biotech shares surge 19.72% premarket after announcing collaboration with CIC biomaGUNE to study Annamycin for glioblastoma treatment.

Moleculin Biotech surged 19.72% in premarket trading following the announcement of a collaboration with CIC biomaGUNE to evaluate Annamycin for glioblastoma multiforme (GBM), a high-unmet-need indication. The partnership involves preclinical studies comparing intra-arterial delivery of Annamycin against existing therapies in mouse models. Concurrently, the company reported progress in its pivotal MIRACLE Phase 3 trial for acute myeloid leukemia (AML), including treatment completion for 45 patients and accelerated recruitment. These developments, combined with recent patent expansions and positive AML survival data, underscored investor optimism about Annamycin’s therapeutic potential and regulatory pathway advancements. The collaboration with a prestigious research institution and ongoing trial milestones reinforced confidence in Moleculin’s pipeline, driving the sharp premarket rally.